Welcome to our dedicated page for Camp4 Therapeutics SEC filings (Ticker: CAMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CAMP4 Therapeutics Corporation filings document a clinical-stage biopharmaceutical issuer focused on regulatory RNA-targeting antisense oligonucleotide therapeutics. Its 8-K reports furnish operating results, corporate presentations and program updates for CMP-002 and the company's broader regRNA mapping and ASO discovery work, while material-agreement disclosures describe research, collaboration and license arrangements tied to neurodegenerative and kidney disease targets.
Proxy materials cover board elections, auditor ratification and equity incentive plan matters. Other filings address director appointments, compensatory arrangements, stock-based compensation, capital-structure disclosures, shareholder voting matters and the company’s emerging growth company status.
CAMP4 Therapeutics reported first quarter 2026 results and highlighted progress in its SYNGAP1 program. The company recorded a net loss of $18.3 million for the quarter, reflecting a non-cash $6.2 million loss from a change in fair value of a derivative tranche liability tied to a prior private placement.
Research and collaboration revenue was $1.3 million, while research and development expenses were $10.2 million and general and administrative expenses were $4.2 million. CAMP4 ended March 31, 2026 with $99.2 million in cash and cash equivalents and expects this to fund planned activities into 2028.
Operationally, the company submitted its first clinical trial regulatory filing for lead candidate CMP-002 in Australia and plans additional global filings in 2026, anticipating a global Phase 1/2 trial in the second half of 2026. CMP-002 received Orphan Designation from the EMA, and CAMP4 initiated a collaboration with CURE SYNGAP1 to support the ProMMiS natural history study.
CAMP4 Therapeutics Corporation is holding its 2026 annual stockholder meeting as a virtual-only webcast on June 10, 2026, at 11:00 a.m. Eastern. Stockholders will vote on electing three Class II directors, ratifying Ernst & Young LLP as auditor, and approving an amendment to the 2024 Equity Incentive Plan.
The record date is April 13, 2026, with 51,925,800 common shares entitled to one vote each. The proxy statement outlines board structure, committee responsibilities, executive and director pay, and severance and change-in-control protections for senior leaders.
Camp4 Therapeutics Corp Chief Scientific Officer Daniel Tardiff received a grant of stock options covering 170,000 shares of common stock. The options have an exercise price of $4.46 per share and expire on March 31, 2036.
The options vest in equal monthly installments over four years starting from the grant date, aligning compensation with long-term company performance. Following this award, Tardiff holds 170,000 stock options directly, reflecting a routine, compensation-related equity grant rather than an open-market trade.
Camp4 Therapeutics reported that Chief Medical Officer Yuri Maricich received a grant of stock options covering 215,000 shares of common stock. The options have an exercise price of $4.46 per share, expire on March 31, 2036, and vest in equal monthly installments over four years from the grant date.
Camp4 Therapeutics Corp Chief Financial Officer Kelly Gold received a grant of stock options covering 215,000 shares of common stock. The options have an exercise price of $4.46 per share and expire in 2036.
The shares underlying the option vest in equal monthly installments over four years from the grant date, meaning the award functions as long-term, time-based compensation rather than an immediate cash transaction.
Camp4 Therapeutics Corp reported that Chief Executive Officer Josh Mandel-Brehm received a grant of stock options on Common Stock. The award covers 580,000 shares with an exercise price of $4.46 per share and an expiration date of March 31, 2036.
The options vest in equal monthly installments over four years starting from the grant date, meaning the award is earned gradually over time. Following this grant, Mandel-Brehm holds stock options covering 580,000 shares directly.
Camp4 Therapeutics director Michael F. MacLean received a new stock option award for 56,000 shares of common stock. The option has an exercise price of $4.46 per share and expires on March 31, 2036. This is a compensation-related grant, not an open-market purchase.
The option covers 56,000 underlying shares and was awarded at no cost on the grant date. The shares underlying the option vest in equal monthly installments over three years starting from the grant date, so MacLean earns the right to exercise portions of the award gradually over time.
Camp4 Therapeutics Corp director Michael F. MacLean filed an initial Form 3, which is the required statement of beneficial ownership when someone becomes an insider. This filing lists him as a director but does not report any buy or sell transactions in the company’s securities.
CAMP4 Therapeutics Corporation announced that its Board of Directors has appointed Michael MacLean as a Class III director, effective April 1, 2026, and expanded the Board from eight to nine members. He will also join the Audit Committee and Compensation Committee.
MacLean brings more than 35 years of financial leadership in biotechnology and life sciences, including serving as Chief Financial Officer of Avidity Biosciences through its IPO and subsequent acquisition by Novartis, and prior senior roles at Akcea Therapeutics, PureTech Health, and Biogen. Under an amended non-employee director compensation policy, he will receive an option to purchase 56,000 shares of CAMP4 common stock, vesting in monthly installments over three years, plus standard cash retainers and the company’s standard director indemnification agreement.